| Literature DB >> 17125251 |
Rachael L Summerfield1, Denis M Daigle, Stanislas Mayer, Debasis Mallik, Donald W Hughes, Sean G Jackson, Margaret Sulek, Michael G Organ, Eric D Brown, Murray S Junop.
Abstract
Dihydrofolate reductase (DHFR) is a vital metabolic enzyme and thus a clinically prominent target in the design of antimetabolites. In this work, we identify 1,4-bis-{[N-(1-imino-1-guanidino-methyl)]sulfanylmethyl}-3,6-dimethyl-benzene (compound 1) as the correct structure of the previously reported DHFR inhibitor 1,4-bis-{(iminothioureidomethyl)aminomethyl}-3,6-dimethyl-benzene (compound 2). The fact that compound 1 has an uncharacteristic structure for DHFR inhibitors, and an affinity (KI of 11.5 nM) comparable to potent inhibitors such as methotrexate and trimethoprim, made this inhibitor of interest for further analysis. We have conducted a characterization of the primary interactions of compound 1 and DHFR using a combination of X-ray structure and SAR analysis. The crystal structure of E. coli DHFR in complex with compound 1 and NADPH reveals that one portion of this inhibitor exploits a unique binding surface, the M20 loop. The importance of this interface was further confirmed by SAR analysis and additional structural characterization.Entities:
Mesh:
Substances:
Year: 2006 PMID: 17125251 DOI: 10.1021/jm060570v
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446